Cancer treatments can cause a wide variety of adverse side effects that require tailored diagnosis and treatment.

The conference, Protein Sciences in Drug Discovery, brought together scientists to discuss high-throughput methods for protein expression, approaches for generation of antigens for antibody and ...

Leerink initiated coverage of Janux Therapeutics (JANX) with an Outperform rating and $79 price target Janux’s TRACTr platform solves the therapeutic window problem that has historically plagued ...

In this randomized controlled trial, adjuvant therapy with durvalumab led to improved overall and progression-free survival ...

As bispecific antibodies gain prominence for their revolutionary therapeutic ... ALG.APV-527 is being evaluated in a Phase 1 trial for solid tumors likely to express the tumor antigen 5T4. Tumor types ...